Why is Transgene Biotek falling/rising?

As of 10-Sep, Transgene Biotek Ltd is currently priced at 3.82, reflecting an increase of 0.13 or 3.52%. Despite this positive movement today, the stock has shown a significant decline over the past month, down 18.38%, and a year-to-date drop of 44.07%. The stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. However, there has been a notable increase in investor participation, with delivery volume rising by 137.51% against the 5-day average, suggesting a growing interest in the stock despite its overall downward trajectory. Unfortunately, there is no specific positive or negative dashboard data available to further clarify the factors influencing the stock's recent movement.
In the broader market context, Transgene Biotek's performance over the past week has been underwhelming, with a decline of 0.78%, while the benchmark Sensex has increased by 1.06%. This underperformance relative to the benchmark highlights the challenges the stock faces in gaining traction in the market. Over the past month, the stark contrast continues, with the stock's 18.38% decline compared to the Sensex's modest gain of 1.96%. This suggests that while there may be short-term gains today, the overall sentiment around Transgene Biotek remains cautious, especially when compared to the broader market trends.